Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 4:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 11,591 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: CHRONIC DISEASE Clear all

Conditions: Leukemia, Lymphoma
Interventions: bryostatin 1, vincristine sulfate; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2001
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Cystic Fibrosis
Interventions: Discontinuation of dornase alfa (Dnase), Continuation of dornase alfa (Dnase); Other
Lead sponsor: Nicole Hamblett; Other
Eligibility: 12 Years and older
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 81
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more

Conditions: Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia
Interventions: G-CSF mobilized CD34+ selected cells for transplantation; Biological
Lead sponsor: Emory University; Other
Eligibility: 17 Years to 75 Years
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hematologic Neoplasms
Interventions: donor lymphocyte infusion, Cyclophosphamide, Busulfan, Mycophenolate mofetil, Fludarabine, Sirolimus; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 120 Years
Enrollment: 430 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cerebral Palsy, Stroke, Premature Birth, Hypoxic-Ischemic Encephalopathy, Periventricular Leukomalacia
Interventions: Mobility Device, Spinal Stimulation; Device
Lead sponsor: University of Washington; Other
Eligibility: 4 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: busulfan, cyclophosphamide, methylprednisolone, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation; Drug · Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 19 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 2
States / cities: Baltimore, Maryland • Columbia, South Carolina

Conditions: Chronic Pain, PERIPHERAL NEUROPATHY, Occipital Neuralgia, Chronic Hip Pain, Hip Osteoarthritis, Knee Osteoarthritis, Spasticity, Chronic Low Back Pain, Lumbar Spondylosis, Cervical Spondylosis, Shoulder Arthritis, Causalgia, Chronic Pain Syndrome, Chronic Neck Pain
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Old Saybrook, Connecticut

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chemotherapy-Related Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Langerhans Cell Histiocytosis, Minimal Residual Disease, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Myelodysplastic Syndrome, Small Lymphocytic Lymphoma, Therapy-Related Myelodysplastic Syndrome
Interventions: Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Filgrastim-sndz, Fludarabine, Melphalan, Mycophenolate Mofetil, Rituximab, Tacrolimus, Total-Body Irradiation, Umbilical Cord Blood Transplantation; Biological · Drug · Radiation + 1 more
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years to 65 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Secondary Progressive Multiple Sclerosis
Interventions: Foralumab, Placebo; Drug · Other
Lead sponsor: Tiziana Life Sciences LTD; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: North Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 4 more

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: decitabine; Drug
Lead sponsor: California Cancer Consortium; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 4
States / cities: Duarte, California • Los Angeles, California • Sacramento, California

Conditions: Chronic Idiopathic Urticaria
Interventions: etanercept, placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: End-Stage Renal Disease, Hemodialysis
Interventions: CP-690,550; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 2
States / cities: Orlando, Florida • Minneapolis, Minnesota

Conditions: Myofascial Pain Syndrome (MPS), Chronic Low-back Pain (cLBP)
Interventions: Acupuncture, Sham Acupuncture, Total-Body PET/CT Imaging; Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Urticaria Chronic
Interventions: Briquilimab; Drug
Lead sponsor: Jasper Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 10 more

Conditions: Respiration, Artificial, Critical Illness, Chronic Disease, Exercise Therapy, Rehabilitation, Physical Therapy Modalities
Interventions: multimodal physical therapy; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 20 Years to 100 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Plaque Psoriasis
Interventions: Bimekizumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Bexley, Ohio

Conditions: Chronic Lymphocytic Leukemia, 17p Deletion, Cancer of the Blood and Bone Marrow
Interventions: ABT-199 (Main Cohort), ABT-199 (Safety Expansion Cohort); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 16
States / cities: Tucson, Arizona • Duarte, California • La Jolla, California + 11 more

Conditions: Sinusitis, Chronic Sinusitis
Interventions: Bacitracin, Nasopore sponge soaked with saline; Drug · Procedure
Lead sponsor: Lahey Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Primary Progressive Multiple Sclerosis
Interventions: Tolebrutinib, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 767 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 45
States / cities: La Jolla, California • Los Alamitos, California • Los Angeles, California + 41 more

Conditions: Lymphoma
Interventions: rituximab, cyclophosphamide, dexamethasone, lenalidomide; Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 2
States / cities: Scottsdale, Arizona • Rochester, Minnesota

Conditions: COPD, Smoking
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Anaemia
Interventions: GSK1278863, rhEPO; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 25
States / cities: Peoria, Arizona • Azusa, California • La Mesa, California + 21 more

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: anti-thymocyte globulin, sargramostim, busulfan, fludarabine phosphate, mycophenolate mofetil, tacrolimus, umbilical cord blood transplantation; Biological · Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 70 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Asthma, COPD
Interventions: n-acetylcystine (NAC)+ albuterol, AeroEclipse-VersaPAP System; Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study

Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Spinal Stimulation and Mobility Devices

Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Prospective Case Series Evaluating 6-Month and 12-Month Outcomes After Cryoneurolysis for Chronic Pain

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Decitabine in Treating Patients With Melanoma or Other Advanced Cancer

Etanercept for the Treatment of Chronic Urticaria

Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease

Imaging Metabolic and Perfusion Changes in Acupuncture Therapy for Myofascial Pain Syndrome

A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials

Development of a Rehabilitation Strengthening and Mobility Program for Ventilator Dependent Older Patients

A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

Pilot Study To Evaluate A Pharmacologically Active Nasal Sponge Following Endoscopic Sinus Surgery

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma

Modulation of Genes Responsible for Cilia Length by Exposure to Cigarette Smoke

A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)

Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)